908 Devices (MASS) FY Conference August 13, 2025 01:00 PM ET Speaker0Hi, everyone. Good afternoon. My name is Osimohr, Aerospace and Defense Analyst here at Canaccord Genuity. And today, we are joined by hope it's making noise.Speaker1Turned it off.Speaker0You did say that was happening. We're joined by Kevin Knopp, CEO and Joseph Griffith, CFO of nine zero eight devices. Ticker is mass. So I guess, I think just to start off, you wanted to go through our presentation just to begin, and then, I guess we can ...

Financial Data and Key Metrics Changes - Revenue from continuing operations was $13 million, an increase of 14% over the prior year period [5][22] - Adjusted EBITDA loss was $3.9 million for the quarter, an improvement of more than 45% year over year [6][26] - Net loss from continuing operations was $12.9 million compared to $7.6 million in the prior year period [26][27] - Cash, cash equivalents, and marketable securities totaled $118.6 million with no debt outstanding [26] Business Line Data and Key Metrics Changes - Device sales accounted for approximately 60% of revenue from mass spec devices, while FTIR products made up the remaining 40% [5][6] - Handheld product and service revenue was $12.5 million, up 13% from the prior year [22] - Recurring revenue represented 36% of total revenues, amounting to $4.7 million, a 28% increase year over year [23][24] Market Data and Key Metrics Changes - The U.S. Budget FY 2026 reconciliation bill includes over $1.7 billion in funding for various grant programs, representing an approximate 11% increase from 2024 levels [10][11] - The Department of Homeland Security budget saw a 7% year-over-year increase, opening broader procurement opportunities [11] Company Strategy and Development Direction - The company aims to be adjusted EBITDA positive by Q4 2025, focusing on marketing expansion, advancing innovation, and reinforcing financial discipline [6][19] - The launch of Viper, a new handheld chemical analyzer, is expected to strengthen the company's position in global security markets [15][18] - The company is targeting a 20% plus revenue growth for 2026, driven by expanding handheld adoption and launching next-generation products [29][66] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting 2025 targets due to strong legislative support and funding for public safety initiatives [12][13] - The company anticipates that recent U.S. legislative outcomes will institutionalize demand and clarify a growth path across core customer segments [13][14] Other Important Information - The company completed the transfer of manufacturing to a lower-cost facility, enhancing operational efficiency [19][20] - The acquisition of KAF Manufacturing is expected to improve quality control and reduce dependence on external vendors [20][21] Q&A Session Summary Question: Are federal funding items showing up in the order book? - Management indicated that while there are positive tailwinds, it may take time to see acceleration in sales reflecting these factors [39][40] Question: Can the company maintain positive EBITDA after achieving it? - Management noted that seasonality typically affects cash flow, but they are confident in achieving positive adjusted EBITDA in Q4 [42] Question: What is the early uptake of the new product Viper? - Initial feedback on Viper has been positive, with expectations for significant contributions in 2026 [50][53] Question: What is the runway for sustained device placement growth? - Management highlighted that the majority of Explorer orders were funded through new legislation, indicating a strong pipeline for future growth [58][60] Question: How does the company plan to leverage federal budget tailwinds? - Management believes the federal budget increases will support both new customer acquisition and replacement cycles for outdated technologies [82]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-39815 908 DEVICES INC. (Exact name of registrant as specified in its charter) Delaware 45-4524096 (State or ...

Analysis at the speed of life AUGUST 2025 Forward looking statements / Non-GAAP financial measures This presentation and the accompanying oral presentation (this "presentation") contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements may relate to, but are not limited to, expectations of future results of operations or financial performance of 908 Devices Inc ...

Exhibit 99.1 908 Devices Reports Second Quarter 2025 Financial Results and Raises 2025 Revenue Outlook Revenue from continuing operations grew 14% compared to prior year BOSTON – August 5, 2025 – 908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today reported financial results for the quarter ended June 30, 2025. "We executed with urgency and discipline in the second quarter, dri ...

Masivo Highlights Wide Historic High-Grade Results from Cerro Colorado and Announces Equity RaiseJune 27, 2025 11:30 AM EDT | Source: Masivo Silver Corp.Vancouver, British Columbia--(Newsfile Corp. - June 27, 2025) - Masivo Silver Corp. (TSXV: MASS) (OTC Pink: GNYPF) ("Masivo" or the "Company") is pleased to report encouraging historic results from the two known drill holes completed at the drill target for Cerro Colorado Gold-Silver Project in Sonora, Mexico, as the Company advances final due ...

Investors might want to bet on 908 Devices Inc. (MASS) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual inves ...

Strategic Transformation Realized MARCH 5th 2025 designed for 'point-of-need' use in vital health and safety contexts Forward looking statements / Non-GAAP financial measures This presentation and the accompanying oral presentation (this "presentation") contain forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements may relate to, but are not limited to, expectations ...

Strategic Transformation - 908 Devices shifted its focus to high-growth handheld markets, aligning with trends in opioid crisis response, defense budgets, and border security[9] - The company divested its biopharma desktop portfolio to REPLIGEN for $70 million in cash, nearly doubling its balance sheet cash[11] - 908 Devices is targeting adjusted EBITDA profitability by Q4 2025 and cash flow positivity in 2026, driven by improved gross margins and streamlined operations[9] Financial Performance & Guidance - As of March 31, 2025, 908 Devices had $124 million in cash and $52 million in revenue for the last twelve months (LTM)[15] - Q1 2025 recurring revenue was $44 million, representing 37% of total revenue, with a year-over-year growth of 59%[41] - The company's 2025 revenue guidance from continuing operations is $53 million to $55 million, representing a year-over-year growth of +11% to +15%[39] - 908 Devices anticipates an adjusted EBITDA positive by Q4 2025 and expects to have a year-end cash balance of over $110 million[39] - Adjusted gross margin for Q1 2025 was 54%, an increase of 75 basis points year-over-year[41] Growth Catalysts - Equipment modernization, specifically replacing outdated FTIRs, presents a 15,000-unit replacement opportunity[45] - The launch of the next-generation MX908 device is expected to drive enterprise placement wins and generate a replacement cycle from the existing >2,800 MX devices fielded[36] - The U S Department of Defense AVCAD program anticipates an award for full-rate manufacturing, potentially generating >$10 million in annual revenue starting in 2026[37, 45]

Summary of 908 Devices (MASS) FY Conference Call - June 04, 2025 Company Overview - **Company**: 908 Devices - **Industry**: Handheld chemical detection technology for public health, safety, and defense Key Themes and Core Points 1. **Strategic Transformation**: The company has completed a significant transformation, exiting the desktop business and focusing solely on handheld chemical detection, which is expected to enhance operational alignment and financial performance [5][6][11] 2. **Financial Performance**: The company is on track to achieve adjusted EBITDA breakeven by Q4 2025 and anticipates full-year cash flow positivity by 2026 [9][40][42] 3. **Market Opportunity**: The total addressable market (TAM) for handheld devices is projected to reach $2.5 billion by 2027, with the handheld revenue growth outpacing that of the desktop segment [12][40] 4. **Product Portfolio Expansion**: The product lineup has expanded from one to four handheld devices, with plans to increase to six by 2026, enhancing the company's ability to address critical health and safety applications [39][41][43] 5. **Revenue Growth**: Q1 2025 revenue reached $11.8 million, a 59% year-over-year increase, driven by an 86% increase in handheld product and service revenue [47][48] 6. **Recurring Revenue**: Recurring revenue grew by 54% year-over-year, indicating strong demand for services and consumables [48] 7. **Cash Position**: The company ended Q1 2025 with approximately $124 million in cash, bolstered by a $70 million inflow from the divestiture of the desktop business [50] Industry Dynamics 1. **Opioid Crisis**: The company is positioned to address the escalating opioid crisis, with increasing demand for advanced detection technologies to combat synthetic drugs [15][16][18] 2. **Global Security Concerns**: Heightened global security needs are driving demand for modern detection tools, with NATO allies projected to increase defense spending significantly [20][22][23] 3. **Public Funding Trends**: There is a favorable funding environment for public safety technologies, with increased investments across various sectors including law enforcement and military [19][23] Additional Insights 1. **Sales Cycle Variability**: The sales cycle varies significantly across different channels, with state and local sales often turning around quickly, while federal military sales can take years [55][56] 2. **Competitive Positioning**: The company emphasizes its comprehensive service approach and modern technology to compete against legacy products in the market [60] 3. **Future Growth Catalysts**: Key growth drivers include the modernization of outdated FTIR units, the launch of next-generation handheld devices, and the full-rate production of the U.S. DoD AvCAD program, which could add over $10 million in annual revenue potential [32][36][42] Conclusion 908 Devices is undergoing a transformative phase, focusing on handheld chemical detection with a robust product portfolio and a favorable market environment. The company is positioned for sustainable growth, backed by strong financials and macro trends in public health and safety.